Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | CC-97540 |
Trade Name | |
Synonyms | CC 97540|CC97540 |
Drug Descriptions |
CC-97540 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, a cell surface tumor antigen, potentially leading to an immune response against CD19-expressing tumor cells and inducing cytotoxicity (NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C175049 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CC-97540 | CC-97540 | 0 | 1 |